University of Nottingham
nottingham.ac.ukTotal trials
449
Active
71
Phase 3
12
Total enrollment
1,051,913
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Linaclotide 290 micrograms | — | — | — | — | — | 1 | |
| Lactose placebo pill | — | — | — | — | — | 1 | |
| Rapamune (sirolimus) 1Mg | — | — | — | — | — | 1 |
Next readouts
- 2026-08
- 2027-05-01
Top conditions
- Healthy16
- Obesity14
- Stroke12
- Multiple Sclerosis11
- Irritable Bowel Syndrome11
- Asthma11
- Sarcopenia10
- Insulin Resistance9
Frequently asked questions about University of Nottingham
- How many clinical trials does University of Nottingham have on ClinicalTrials.gov?
- University of Nottingham is listed as the lead sponsor on 449 clinical trials in ClinicalTrials.gov, 71 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Nottingham's trials are in Phase 3?
- 12 of University of Nottingham's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does University of Nottingham focus on?
- University of Nottingham's most-studied conditions on ClinicalTrials.gov are Healthy, Obesity, Stroke, Multiple Sclerosis, Irritable Bowel Syndrome.
- When are University of Nottingham's next clinical trial readouts?
- University of Nottingham has 2 upcoming primary-completion readouts tracked here; the soonest is “Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis”, expected around 2026-08.